|
Winter 2010
Issue No. 1
Xplore
RTSM Reporting
ClinPhone® RTSM (Randomization and Trial Supply Management) has introduced powerful new reporting functionalities to help customers answer key questions through intelligent analysis and presentation of their RTSM study data. The reporting solution is built upon our unrivaled experience of providing RTSM applications for over 2,800 clinical trials, together with extensive research into how our customers are utilizing RTSM data to monitor the progress of their clinical trials.
Designed for optimal performance to ensure quick and efficient access to study data and metrics, the ClinPhone RTSM reporting solution comes in three modules:
- Universal Report Suite - An online and scheduled suite of reports delivered with all ClinPhone RTSM studies
- RTSM Dashboard - Provides high-level metrics and forecasting data to aid strategic decision making
- Self-Service Module - Enables users to create and download their own datasets from the live study database
Our reporting solution’s cutting-edge, advanced features include:
- Built-in capabilities to chart, graph and export data into users’ study documents and reports
- Download data in a variety of formats including Excel®, PowerPoint®, PDF and Active HTML files
- Download and sharing of reports, enabling local display and interrogation of data using a snapshot of the live database
- Graphical displays of trends and forecasts to enhance data interpretation
Why not check it out for yourself? Click here to find out more.
RECIST 1.1
Perceptive has released its RECIST 1.1 toolset to help investigators apply the new version of RECIST (Response Evaluation Criteria In Solid Tumors) in medical imaging-based oncology trials.
RECIST is an important set of published rules that define when cancer patients improve, stay the same or worsen during treatments, and is used by the majority of today’s clinical trials evaluating cancer treatments for solid tumors. The benefits of the new 1.1 version, published in January 2009, include more robust data analysis for patients with certain disease indications as well as the ability to incorporate long-awaited enhancements to evaluate certain types of cancer treatments.
Perceptive’s RECIST 1.1 toolset includes our cutting-edge, proprietary image analysis and measurement technology which has been updated to support the new criteria. To help educate on the optimal use of RECIST, we have introduced the www.recist.com website, providing an extensive comparison between RECIST 1.0 and 1.1, and our RECIST Kiosk offers computer-based training for investigators. With a proven track record of thought leadership in medical imaging and having actively participated in the RECIST Working Group, Perceptive is leading the way in incorporating the RECIST criteria into Independent Review Charters for regulatory approval of oncology treatments.
Click here to find out more.
|
